A Phase 1/2 interventional study of RSV Vaccine (GSK3844766A) unadjuvanted low dose and RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 21 sites in 2 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-05.
Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline — 1 open to participants now, 5 under way, 3 of them phase 3. Respiratory Syncytial Virus Infections · GlaxoSmithKline.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 13th largest by enrollment, is one of 6 that started in 2019, is one of 4 in phase 1/2, and was the 11th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline is open now, in 2 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Australia
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 13 · Phase 3 21
First in 2013; this study’s year is marked. 6 started in 2019.
This study's enrollment of 1,053 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 642 across the 40 interventional studies. Of the 33 that completed or were terminated, 30 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07092865GlaxoSmithKlineA Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant | 2027-01-12 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, reactogenicity and immune responses of two doses of the investigational RSV vaccines (with different formulations), when administered intramuscularly (IM) according to a 0, 2 month schedule, in older adults aged 60 to 80 years.
As the investigational vaccines have not yet been tested in humans before, the study will first assess the safety, reactogenicity and immune responses in young adults aged 18 to 40 years. The study will thus be conducted in 2 parts (Part A and Part B).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For all subjects:
For Part A:
For Part B:
Exclusion Criteria:
For all subjects:
For Part A:
Female subjects of , except if the subject:
For Part B:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in Part A, aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Biological: RSV Vaccine (GSK3844766A) unadjuvanted low dose
Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Biological: RSV Vaccine (GSK3844766A) unadjuvanted medium dose
Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Biological: RSV Vaccine (GSK3844766A) unadjuvanted high dose
Subjects in Part A aged 18-40 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Drug: Placebo (Saline solution)
Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Biological: RSV Vaccine (GSK3844766A) unadjuvanted low dose
Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Biological: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E
Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Biological: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B
Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Biological: RSV Vaccine (GSK3844766A) unadjuvanted medium dose
Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Biological: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E
Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Biological: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B
Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Biological: RSV Vaccine (GSK3844766A) unadjuvanted high dose
Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Biological: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E
Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Biological: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B
Subjects in Part B aged 60-80 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Drug: Placebo (Saline solution)
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose
Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored as injection site erythema/swelling with a diameter larger than (\>) 20 millimeters (mm)
Time frame: During a 7-day follow-up period after first vaccination dose (i.e., on the day of vaccination [at Day 1] and 6 subsequent days)
Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose
Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored as injection site erythema/swelling with a diameter larger than (\>) 20 millimeters (mm)
Time frame: During a 7-day follow-up period after second vaccination dose (i.e., on the day of vaccination [at Day 61] and 6 subsequent days)
Number of Subjects With Any Solicited General Symptom After First Vaccination Dose
Assessed solicited general symptoms include arthralgia, fatigue, fever \[defined as temperature equal to or above 38.0 degrees Celsius (°C)\], gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], headache, myalgia and shivering.
Time frame: During a 7-day follow-up period after the first vaccination dose (i.e., on the day of vaccination [at Day 1] and 6 subsequent days)
Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose
Assessed solicited general symptoms include arthralgia, fatigue, fever \[defined as temperature equal to or above 38.0 degrees Celsius (°C)\], gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], headache, myalgia and shivering.
Time frame: During a 7-day follow-up period after the second vaccination dose (i.e., on the day of vaccination [at Day 61] and 6 subsequent days)
Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During a 30-day follow-up period (i.e., on the day of vaccination and 29 subsequent days) after any vaccination dose (across doses)
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups)
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.
Time frame: At baseline and at 7 days after the first vaccine dose (Day 8)
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups)
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.
Time frame: At baseline and at 7 days after the first vaccine dose (Day 8)
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups)
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.
Time frame: At baseline and at 7 days after the second vaccine dose (Day 68)
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups)
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.
Time frame: At baseline and at 7 days after the second vaccine dose (Day 68)
Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination
A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.
Time frame: During a 30-day follow-up period (i.e., on the day of vaccination at Day 1, and 29 subsequent days) after first dose of vaccination
Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination
A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.
Time frame: During a 30-day follow-up period (i.e., on the day of vaccination at Day 61, and 29 subsequent days) after second dose of vaccination
Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.
Time frame: From first vaccination (Day 1) up to 30 days post second vaccination (Day 91)
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups)
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: From first vaccination (Day 1) up to 30 days post second vaccination (Day 91)
Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: From Day 1 up to the end of follow-up period (Month 14)
Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: From Day 1 up to the end of follow-up period (Month 14)
Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups
The number of subjects with at least one RTI case was provided by group. Reported categories are RSV+ (= RTI episode tested as RSV positive by quantitative reverse transcription polymerase chain reaction (qRT-PCR) on nasal/throat swab) and RSV- (= RTI episode tested as RSV negative by qRT-PCR on nasal/throat swab).
Time frame: During the RSV season (from October 2019 to March 2020)
Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A
Serological assays for the determination of functional antibodies against RSV-A were performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as geometric mean titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60).
Time frame: At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)
Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations
The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples were based on an indirect enzyme-linked immunosorbent assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL).
Time frame: At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)
Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers
Among markers expressed were interleukin-2 (IL2), cluster of 40 ligand (CD40L), tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations. Reported statistics at each time point during which blood sample were collected for cell-mediated immunity, are geometric mean and inter-quartile range.
Time frame: At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)
| Milestone | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 12 | 12 | 12 | 101 | 97 | 100 | 101 | 101 | 100 | 103 | 100 | 101 | 101 |
| Completed | 12 | 10 | 11 | 12 | 100 | 92 | 97 | 95 | 101 | 95 | 100 | 100 | 97 | 98 |
| Not completed | 0 | 2 | 1 | 0 | 1 | 5 | 3 | 6 | 0 | 5 | 3 | 0 | 4 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Consent withdrawal, due to covid-19 but not due to an adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Consent withdrawal, not due to covid-19 and not due to an adverse event | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 2 | 0 | 3 | 1 | 0 | 1 | 2 |
| Withdrew: Migrated / moved from the study area | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Unknown reason | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored as injection site erythema/swelling with a diameter larger than (\>) 20 millimeters (mm)
| Participants | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 5 | 6 | 9 | 16 | 15 | 18 | 1 |
| Pain | 1 | 7 | 6 | 0 | 9 | 5 | 14 | 54 | 57 | 56 | 78 | 63 | 76 | 4 |
| Swelling | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 7 | 7 | 6 | 10 | 7 | 9 | 0 |
Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored as injection site erythema/swelling with a diameter larger than (\>) 20 millimeters (mm)
| Participants | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 3 | 7 | 16 | 14 | 12 | 0 |
| Pain | 5 | 7 | 8 | 1 | 18 | 18 | 23 | 34 | 48 | 47 | 58 | 56 | 59 | 4 |
| Swelling | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 3 | 6 | 10 | 7 | 10 | 0 |
Assessed solicited general symptoms include arthralgia, fatigue, fever \[defined as temperature equal to or above 38.0 degrees Celsius (°C)\], gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], headache, myalgia and shivering.
| Participants | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arthralgia | 0 | 0 | 0 | 0 | 7 | 4 | 0 | 7 | 12 | 6 | 15 | 9 | 17 | 7 |
| Fatigue | 4 | 5 | 1 | 6 | 22 | 11 | 24 | 26 | 28 | 21 | 30 | 29 | 49 | 16 |
| Fever | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 1 | 3 | 3 | 1 | 0 |
| Gastrointestinal symptoms | 1 | 2 | 1 | 1 | 8 | 8 | 10 | 8 | 8 | 9 | 13 | 7 | 13 | 10 |
| Headache | 2 | 4 | 3 | 2 | 8 | 7 | 13 | 20 | 12 | 17 | 28 | 27 | 28 | 8 |
| Myalgia | 0 | 1 | 1 | 0 | 4 | 3 | 1 | 9 | 8 | 6 | 19 | 12 | 18 | 5 |
| Shivering | 0 | 2 | 0 | 1 | 1 | 1 | 2 | 6 | 5 | 3 | 12 | 8 | 16 | 1 |
Assessed solicited general symptoms include arthralgia, fatigue, fever \[defined as temperature equal to or above 38.0 degrees Celsius (°C)\], gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], headache, myalgia and shivering.
| Participants | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arthralgia | 0 | 0 | 0 | 0 | 1 | 4 | 2 | 8 | 8 | 10 | 21 | 11 | 13 | 4 |
| Fatigue | 3 | 2 | 4 | 5 | 16 | 11 | 13 | 24 | 22 | 24 | 35 | 35 | 34 | 16 |
| Fever | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 4 | 6 | 3 | 0 |
| Gastrointestinal symptoms | 1 | 1 | 2 | 2 | 4 | 2 | 7 | 7 | 5 | 7 | 11 | 7 | 9 | 6 |
| Headache | 2 | 2 | 3 | 3 | 11 | 9 | 8 | 15 | 18 | 10 | 33 | 26 | 18 | 9 |
| Myalgia | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 6 | 9 | 11 | 19 | 12 | 18 | 2 |
| Shivering | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 3 | 4 | 14 | 12 | 9 | 2 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose | 2 | 4 | 4 | 6 | 34 | 28 | 30 | 40 | 29 | 36 | 39 | 34 | 43 | 33 |
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.
| Participants | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group |
|---|---|---|---|---|
| ALT-WITHIN-WITHIN | 12 | 12 | 11 | 12 |
| AST-WITHIN-WITHIN | 11 | 12 | 11 | 11 |
| AST-ABOVE-WITHIN | 1 | 0 | 0 | 1 |
| Basophils-WITHIN-WITHIN | 12 | 12 | 11 | 12 |
| Creatinine-BELOW-BELOW | 0 | 0 | 0 | 1 |
| Creatinine-BELOW-WITHIN | 1 | 2 | 0 | 0 |
| Creatinine-WITHIN-WITHIN | 11 | 9 | 11 | 11 |
| Creatinine-ABOVE-ABOVE | 0 | 1 | 0 | 0 |
| Eosinophils-BELOW-BELOW | 0 | 1 | 0 | 0 |
| Eosinophils-BELOW-WITHIN | 0 | 0 | 1 | 0 |
| Eosinophils-WITHIN-WITHIN | 11 | 10 | 10 | 12 |
| Eosinophils-ABOVE-WITHIN | 1 | 1 | 0 | 0 |
| Erythrocytes-BELOW-WITHIN | 1 | 0 | 0 | 1 |
| Erythrocytes-WITHIN-WITHIN | 11 | 11 | 11 | 11 |
| Erythrocytes-ABOVE-WITHIN | 0 | 1 | 0 | 0 |
| Hemoglobin-BELOW-BELOW | 0 | 0 | 0 | 1 |
| Hemoglobin-BELOW-WITHIN | 1 | 0 | 0 | 0 |
| Hemoglobin-WITHIN-WITHIN | 11 | 12 | 11 | 11 |
| Lymphocytes-BELOW-WITHIN | 0 | 1 | 0 | 1 |
| Lymphocytes-WITHIN-WITHIN | 12 | 11 | 11 | 11 |
| Monocytes-BELOW-WITHIN | 0 | 1 | 0 | 0 |
| Monocytes-WITHIN-WITHIN | 12 | 11 | 11 | 12 |
| Neutrophis-BELOW-BELOW | 0 | 0 | 1 | 0 |
| Neutrophils-BELOW-WITHIN | 2 | 1 | 0 | 0 |
| Neutrophils-WITHIN-WITHIN | 8 | 11 | 10 | 12 |
| Neutrophils-ABOVE-WITHIN | 1 | 0 | 0 | 0 |
| Neutrophils-ABOVE-ABOVE | 1 | 0 | 0 | 0 |
| Platelets-WITHIN-WITHIN | 12 | 12 | 11 | 12 |
| Urea Nitrogen-WITHIN-BELOW | 0 | 0 | 0 | 1 |
| Urea Nitrogen-WITHIN-WITHIN | 12 | 12 | 11 | 11 |
| Uric Acid-BELOW-WITHIN | 1 | 0 | 0 | 0 |
| Uric Acid-WITHIN-WITHIN | 11 | 12 | 11 | 12 |
| White Blood Cells-BELOW-BELOW | 0 | 1 | 0 | 0 |
| White Blood Cells-BELOW-WITHIN | 2 | 0 | 1 | 1 |
| White Blood Cells-WITHIN-WITHIN | 8 | 11 | 10 | 11 |
| White Blood Cells-ABOVE-WITHIN | 1 | 0 | 0 | 0 |
| White Blood Cells-ABOVE-ABOVE | 1 | 0 | 0 | 0 |
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.
| Participants | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|
| ALT-WITHIN-UNKNOWN | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| ALT-WITHIN-WITHIN | 99 | 97 | 98 | 97 | 98 | 100 | 100 | 94 | 98 | 98 |
| ALT-WITHIN-ABOVE | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| ALT-ABOVE-WITHIN | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 0 |
| ALT-ABOVE-ABOVE | 1 | 0 | 0 | 2 | 0 | 0 | 3 | 3 | 2 | 1 |
| AST-WITHIN-UNKNOWN | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 1 | 1 |
| AST-WITHIN-WITHIN | 100 | 97 | 98 | 98 | 99 | 98 | 97 | 97 | 98 | 99 |
| AST-WITHIN-ABOVE | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| AST-ABOVE-WITHIN | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| AST-ABOVE-ABOVE | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 0 |
| Basophils-WITHIN-UNKNOWN | 0 | 1 | 0 | 1 | 4 | 2 | 0 | 0 | 0 | 0 |
| Basophils-WITHIN-WITHIN | 100 | 96 | 99 | 99 | 96 | 98 | 103 | 100 | 101 | 100 |
| Basophils-WITHIN-ABOVE | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Creatinine-BELOW-BELOW | 0 | 5 | 4 | 3 | 4 | 0 | 1 | 3 | 2 | 0 |
| Creatinine-BELOW-WITHIN | 1 | 3 | 2 | 0 | 1 | 2 | 3 | 2 | 3 | 1 |
| Creatinine-WITHIN-UNKNOWN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Creatinine-WITHIN-BELOW | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 3 |
| Creatinine-WITHIN-WITHIN | 92 | 83 | 89 | 92 | 92 | 93 | 93 | 90 | 88 | 95 |
| Creatinine-WITHIN-ABOVE | 1 | 1 | 2 | 1 | 2 | 1 | 3 | 1 | 0 | 0 |
| Creatinine-ABOVE-UNKNOWN | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine-ABOVE-WITHIN | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| Creatinine-ABOVE-ABOVE | 4 | 4 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 1 |
| Eosinophils-BELOW-BELOW | 2 | 3 | 4 | 0 | 3 | 5 | 3 | 4 | 2 | 2 |
| Eosinophils-BELOW-WITHIN | 5 | 3 | 1 | 3 | 1 | 2 | 5 | 2 | 3 | 1 |
| Eosinophils-BELOW-ABOVE | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Eosinophils-WITHIN-UNKNOWN | 0 | 1 | 0 | 1 | 4 | 2 | 0 | 0 | 0 | 0 |
| Eosinophils-WITHIN-BELOW | 3 | 1 | 2 | 2 | 1 | 1 | 3 | 5 | 3 | 5 |
| Eosinophils-WITHIN-WITHIN | 85 | 86 | 88 | 91 | 89 | 88 | 88 | 86 | 90 | 90 |
| Eosinophils-WITHIN-ABOVE | 2 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
| Eosinophils-ABOVE-WITHIN | 2 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Eosinophils-ABOVE-ABOVE | 2 | 1 | 0 | 1 | 1 | 1 | 3 | 2 | 2 | 0 |
| Erythrocytes-BELOW-BELOW | 4 | 3 | 0 | 1 | 4 | 3 | 2 | 1 | 1 | 2 |
| Erythrocytes-BELOW-WITHIN | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 1 |
| Erythrocytes-WITHIN-UNKNOWN | 0 | 1 | 0 | 1 | 3 | 2 | 0 | 0 | 0 | 0 |
| Erythrocytes-WITHIN-BELOW | 5 | 1 | 0 | 0 | 3 | 3 | 2 | 1 | 4 | 1 |
| Erythrocytes-WITHIN-WITHIN | 89 | 89 | 95 | 98 | 88 | 89 | 95 | 96 | 93 | 94 |
| Erythrocytes-WITHIN-ABOVE | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Erythrocytes-ABOVE-WITHIN | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 1 | 0 |
| Erythrocytes-ABOVE-ABOVE | 1 | 1 | 1 | 0 | 0 | 2 | 2 | 0 | 0 | 3 |
| Hemoglobin-BELOW-UNKNOWN | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin-BELOW-BELOW | 9 | 5 | 1 | 4 | 7 | 4 | 4 | 3 | 5 | 1 |
| Hemoglobin-BELOW-WITHIN | 1 | 2 | 0 | 1 | 0 | 2 | 0 | 1 | 4 | 1 |
| Hemoglobin-WITHIN-UNKNOWN | 0 | 0 | 0 | 1 | 3 | 2 | 0 | 0 | 0 | 0 |
| Hemoglobin-WITHIN-BELOW | 4 | 3 | 1 | 1 | 1 | 2 | 2 | 3 | 5 | 2 |
| Hemoglobin-WITHIN-WITHIN | 87 | 83 | 96 | 91 | 88 | 90 | 96 | 90 | 86 | 95 |
| Hemoglobin-WITHIN-ABOVE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| Hemoglobin-ABOVE-WITHIN | 0 | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 |
| Hemoglobin-ABOVE-ABOVE | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Lymphocytes-BELOW-BELOW | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 0 | 1 |
| Lymphocytes-BELOW-WITHIN | 1 | 2 | 0 | 2 | 3 | 2 | 2 | 1 | 1 | 0 |
| Lymphocytes-WITHIN-UNKNOWN | 0 | 1 | 0 | 1 | 4 | 2 | 0 | 0 | 0 | 0 |
| Lymphocytes-WITHIN-BELOW | 0 | 1 | 0 | 1 | 1 | 0 | 3 | 0 | 0 | 2 |
| Lymphocytes-WITHIN-WITHIN | 99 | 92 | 99 | 94 | 90 | 94 | 96 | 98 | 100 | 98 |
| Lymphocytes-WITHIN-ABOVE | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Lymphocytes-ABOVE-WITHIN | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes-ABOVE-ABOVE | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Monocytes-BELOW-UNKNOWN | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Monocytes-BELOW-BELOW | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 5 | 2 | 0 |
| Monocytes-BELOW-WITHIN | 3 | 1 | 3 | 2 | 0 | 1 | 5 | 1 | 2 | 3 |
| Monocytes-WITHIN-UNKNOWN | 0 | 1 | 0 | 1 | 4 | 1 | 0 | 0 | 0 | 0 |
| Monocytes-WITHIN-BELOW | 5 | 0 | 2 | 0 | 1 | 3 | 2 | 1 | 4 | 3 |
| Monocytes-WITHIN-WITHIN | 91 | 94 | 94 | 97 | 92 | 91 | 96 | 92 | 93 | 95 |
| Monocytes-WITHIN-ABOVE | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 |
| Neutrophils-BELOW-BELOW | 1 | 0 | 2 | 1 | 1 | 1 | 2 | 0 | 1 | 5 |
| Neutrophils-BELOW-WITHIN | 0 | 1 | 1 | 3 | 0 | 3 | 1 | 1 | 1 | 2 |
| Neutrophils-WITHIN-UNKNOWN | 0 | 1 | 0 | 1 | 4 | 2 | 0 | 0 | 0 | 0 |
| Neutrophils-WITHIN-BELOW | 2 | 1 | 1 | 2 | 2 | 2 | 0 | 1 | 1 | 0 |
| Neutrophils-WITHIN-WITHIN | 98 | 94 | 95 | 89 | 92 | 88 | 98 | 96 | 96 | 93 |
| Neutrophils-WITHIN-ABOVE | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 1 | 2 | 0 |
| Neutrophils-ABOVE-WITHIN | 0 | 0 | 0 | 2 | 0 | 2 | 2 | 1 | 0 | 1 |
| Neutrophils-ABOVE-ABOVE | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets-UNKNOWN-UNKNOWN | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets-BELOW-BELOW | 3 | 1 | 2 | 1 | 1 | 2 | 0 | 1 | 1 | 2 |
| Platelets-BELOW-WITHIN | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 0 | 1 | 0 |
| Platelets-WITHIN-UNKNOWN | 1 | 1 | 0 | 3 | 6 | 3 | 2 | 0 | 1 | 0 |
| Platelets-WITHIN-BELOW | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
| Platelets-WITHIN-WITHIN | 96 | 94 | 94 | 93 | 90 | 93 | 97 | 96 | 96 | 96 |
| Platelets-WITHIN-ABOVE | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 |
| Platelets-ABOVE-WITHIN | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Platelets-ABOVE-ABOVE | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 3 |
| Urea Nitrogen-BELOW-BELOW | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Urea Nitrogen-WITHIN-UNKNOWN | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Urea Nitrogen-WITHIN-BELOW | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Urea Nitrogen-WITHIN-WITHIN | 97 | 96 | 95 | 95 | 97 | 93 | 96 | 96 | 98 | 98 |
| Urea Nitrogen-WITHIN-ABOVE | 1 | 1 | 3 | 2 | 1 | 0 | 2 | 2 | 1 | 1 |
| Urea Nitrogen-ABOVE-WITHIN | 0 | 0 | 1 | 0 | 2 | 5 | 2 | 2 | 0 | 1 |
| Urea Nitrogen-ABOVE-ABOVE | 3 | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 1 | 0 |
| Uric Acid-BELOW-BELOW | 1 | 0 | 0 | 3 | 0 | 1 | 5 | 3 | 2 | 2 |
| Uric Acid-BELOW-WITHIN | 0 | 2 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 1 |
| Uric Acid-WITHIN-UNKNOWN | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Uric Acid-WITHIN-BELOW | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 1 |
| Uric Acid-WITHIN-WITHIN | 94 | 91 | 96 | 93 | 98 | 90 | 89 | 88 | 95 | 89 |
| Uric Acid-WITHIN-ABOVE | 1 | 3 | 0 | 2 | 1 | 1 | 3 | 1 | 0 | 3 |
| Uric Acid-ABOVE-WITHIN | 2 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | 3 | 2 |
| Uric Acid-ABOVE-ABOVE | 3 | 0 | 2 | 1 | 0 | 3 | 1 | 3 | 0 | 2 |
| White Blood Cells-BELOW-UNKNOWN | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| White Blood Cells-BELOW-BELOW | 1 | 0 | 2 | 2 | 2 | 1 | 3 | 0 | 1 | 4 |
| White Blood Cells-BELOW-WITHIN | 2 | 1 | 2 | 4 | 1 | 3 | 2 | 4 | 4 | 6 |
| White Blood Cells-WITHIN-UNKNOWN | 0 | 1 | 0 | 1 | 4 | 1 | 0 | 0 | 0 | 0 |
| White Blood Cells-WITHIN-BELOW | 2 | 2 | 3 | 2 | 1 | 3 | 1 | 1 | 0 | 1 |
| White Blood Cells-WITHIN-WITHIN | 94 | 91 | 91 | 87 | 89 | 87 | 95 | 91 | 93 | 90 |
| White Blood Cells-WITHIN-ABOVE | 0 | 1 | 1 | 1 | 1 | 2 | 0 | 2 | 2 | 0 |
| White Blood Cells-ABOVE-WITHIN | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 2 | 1 | 0 |
| White Blood Cells-ABOVE-ABOVE | 1 | 1 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 |
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.
| Participants | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group |
|---|---|---|---|---|
| ALT-WITHIN-WITHIN | 11 | 10 | 10 | 12 |
| ALT-WITHIN-ABOVE | 1 | 0 | 0 | 0 |
| ALT-ABOVE-WITHIN | 0 | 0 | 1 | 0 |
| AST-WITHIN-WITHIN | 10 | 10 | 11 | 12 |
| AST-WITHIN-ABOVE | 1 | 0 | 0 | 0 |
| AST-ABOVE-ABOVE | 1 | 0 | 0 | 0 |
| Basophils-UNKNOWN-WITHIN | 1 | 0 | 0 | 0 |
| Basophils-WITHIN-WITHIN | 11 | 10 | 11 | 12 |
| Creatinine-BELOW-BELOW | 0 | 0 | 0 | 1 |
| Creatinine-WITHIN-WITHIN | 12 | 7 | 11 | 10 |
| Creatinine-WITHIN-ABOVE | 0 | 2 | 0 | 0 |
| Creatinine-ABOVE-WITHIN | 0 | 0 | 0 | 1 |
| Creatinine-ABOVE-ABOVE | 0 | 1 | 0 | 0 |
| Eosinophils-UNKNOWN-WITHIN | 1 | 0 | 0 | 0 |
| Eosinophils-BELOW-BELOW | 0 | 0 | 1 | 0 |
| Eosinophils-BELOW-WITHIN | 0 | 1 | 0 | 0 |
| Eosinophils-WITHIN-BELOW | 1 | 0 | 1 | 0 |
| Eosinophils-WITHIN-WITHIN | 10 | 9 | 8 | 12 |
| Eosinophils-WITHIN-ABOVE | 0 | 0 | 1 | 0 |
| Erythrocytes-UNKNOWN-BELOW | 1 | 0 | 0 | 0 |
| Erythrocytes-WITHIN-BELOW | 1 | 0 | 0 | 0 |
| Erythrocytes-WITHIN-WITHIN | 10 | 9 | 10 | 12 |
| Erythrocytes-WITHIN-ABOVE | 0 | 0 | 1 | 0 |
| Erythrocytes-ABOVE-ABOVE | 0 | 1 | 0 | 0 |
| Hemoglobin-UNKNOWN-BELOW | 1 | 0 | 0 | 0 |
| Hemoglobin-BELOW-WITHIN | 0 | 0 | 1 | 0 |
| Hemoglobin-WITHIN-WITHIN | 11 | 10 | 9 | 12 |
| Hemoglobin-WITHIN-ABOVE | 0 | 0 | 1 | 0 |
| Lymphocytes-UNKNOWN-WITHIN | 1 | 0 | 0 | 0 |
| Lymphocytes-BELOW-WITHIN | 0 | 0 | 0 | 1 |
| Lymphocytes-WITHIN-WITHIN | 11 | 10 | 11 | 11 |
| Monocytes-UNKNOWN-WITHIN | 1 | 0 | 0 | 0 |
| Monocytes-BELOW-WITHIN | 0 | 0 | 1 | 0 |
| Monocytes-WITHIN-WITHIN | 11 | 10 | 10 | 12 |
| Neutrophils-UNKNOWN-WITHIN | 1 | 0 | 0 | 0 |
| Neutrophils-BELOW-BELOW | 0 | 0 | 1 | 0 |
| Neutrophils-BELOW-WITHIN | 1 | 0 | 0 | 0 |
| Neutrophils-WITHIN-BELOW | 1 | 0 | 0 | 0 |
| Neutrophils-WITHIN-WITHIN | 9 | 10 | 10 | 12 |
| Platelets-UNKNOWN-WITHIN | 1 | 1 | 0 | 0 |
| Platelets-WITHIN-WITHIN | 11 | 8 | 11 | 12 |
| Platelets-ABOVE-WITHIN | 0 | 1 | 0 | 0 |
| Urea Nitrogen-WITHIN-WITHIN | 12 | 10 | 11 | 12 |
| Uric Acid-BELOW-WITHIN | 1 | 0 | 0 | 0 |
| Uric Acid-WITHIN-WITHIN | 11 | 10 | 11 | 12 |
| White Blood Cells-UNKNOWN-WITHIN | 1 | 0 | 0 | 0 |
| White Blood Cells-BELOW-BELOW | 1 | 0 | 1 | 0 |
| White Blood Cells-BELOW-WITHIN | 1 | 0 | 0 | 0 |
| White Blood Cells-WITHIN-BELOW | 1 | 0 | 0 | 0 |
| White Blood Cells-WITHIN-WITHIN | 7 | 10 | 10 | 12 |
| White Blood Cells-ABOVE-WITHIN | 1 | 0 | 0 | 0 |
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.
| Participants | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|
| ALT-UNKNOWN-WITHIN | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 0 |
| ALT-WITHIN-UNKNOWN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| ALT-WITHIN-WITHIN | 93 | 94 | 95 | 93 | 94 | 94 | 95 | 91 | 90 | 96 |
| ALT-WITHIN-ABOVE | 2 | 0 | 0 | 0 | 2 | 2 | 0 | 2 | 1 | 0 |
| ALT-ABOVE-WITHIN | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 2 | 0 |
| ALT-ABOVE-ABOVE | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 2 |
| AST-UNKNOWN-WITHIN | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 0 |
| AST-WITHIN-UNKNOWN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| AST-WITHIN-WITHIN | 94 | 93 | 95 | 93 | 97 | 94 | 95 | 93 | 92 | 97 |
| AST-WITHIN-ABOVE | 2 | 0 | 0 | 1 | 0 | 2 | 0 | 2 | 1 | 0 |
| AST-ABOVE-WITHIN | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| AST-ABOVE-ABOVE | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 1 | 1 |
| Basophils-UNKNOWN-WITHIN | 1 | 0 | 1 | 0 | 2 | 2 | 2 | 1 | 2 | 1 |
| Basophils-WITHIN-UNKNOWN | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Basophils-WITHIN-WITHIN | 95 | 94 | 94 | 96 | 95 | 94 | 96 | 96 | 95 | 97 |
| Creatinine-UNKNOWN-BELOW | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Creatinine-UNKNOWN-WITHIN | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 |
| Creatinine-UNKNOWN-ABOVE | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Creatinine-BELOW-UNKNOWN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Creatinine-BELOW-BELOW | 0 | 4 | 2 | 2 | 4 | 1 | 2 | 3 | 1 | 0 |
| Creatinine-BELOW-WITHIN | 3 | 2 | 1 | 1 | 0 | 0 | 1 | 3 | 6 | 0 |
| Creatinine-WITHIN-BELOW | 1 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 1 | 0 |
| Creatinine-WITHIN-WITHIN | 83 | 81 | 86 | 87 | 88 | 90 | 88 | 86 | 83 | 96 |
| Creatinine-WITHIN-ABOVE | 3 | 0 | 2 | 0 | 1 | 1 | 3 | 1 | 3 | 1 |
| Creatinine-ABOVE-WITHIN | 2 | 2 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 |
| Creatinine-ABOVE-ABOVE | 4 | 3 | 2 | 1 | 1 | 1 | 0 | 2 | 1 | 1 |
| Eosinophils-UNKNOWN-WITHIN | 1 | 0 | 1 | 0 | 2 | 1 | 2 | 1 | 2 | 1 |
| Eosinophils-UNKNOWN-ABOVE | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Eosinophils-BELOW-UNKNOWN | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Eosinophils-BELOW-BELOW | 3 | 2 | 4 | 2 | 3 | 4 | 1 | 1 | 4 | 3 |
| Eosinophils-BELOW-WITHIN | 3 | 3 | 5 | 4 | 5 | 1 | 5 | 7 | 2 | 5 |
| Eosinophils-WITHIN-UNKNOWN | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Eosinophils-WITHIN-BELOW | 2 | 2 | 4 | 6 | 3 | 1 | 6 | 1 | 3 | 0 |
| Eosinophils-WITHIN-WITHIN | 82 | 85 | 78 | 79 | 79 | 83 | 78 | 83 | 83 | 87 |
| Eosinophils-WITHIN-ABOVE | 2 | 0 | 0 | 2 | 1 | 3 | 1 | 3 | 1 | 0 |
| Eosinophils-ABOVE-WITHIN | 1 | 1 | 2 | 2 | 0 | 1 | 4 | 1 | 0 | 2 |
| Eosinophils-ABOVE-ABOVE | 2 | 1 | 1 | 1 | 4 | 1 | 1 | 0 | 2 | 0 |
| Erythrocytes-UNKNOWN-BELOW | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Erythrocytes-UNKNOWN-WITHIN | 1 | 0 | 1 | 0 | 1 | 2 | 2 | 1 | 2 | 0 |
| Erythrocytes-UNKNOWN-ABOVE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Erythrocytes-BELOW-BELOW | 6 | 2 | 0 | 1 | 3 | 4 | 2 | 0 | 2 | 1 |
| Erythrocytes-BELOW-WITHIN | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 | 0 |
| Erythrocytes-WITHIN-UNKNOWN | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Erythrocytes-WITHIN-BELOW | 3 | 3 | 0 | 1 | 2 | 3 | 1 | 0 | 1 | 3 |
| Erythrocytes-WITHIN-WITHIN | 83 | 88 | 91 | 92 | 89 | 83 | 89 | 94 | 89 | 92 |
| Erythrocytes-WITHIN-ABOVE | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Erythrocytes-ABOVE-WITHIN | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 |
| Erythrocytes-ABOVE-ABOVE | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 1 | 1 |
| Hemoglobin-UNKNOWN-BELOW | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin-UNKNOWN-WITHIN | 1 | 0 | 1 | 0 | 0 | 2 | 2 | 1 | 2 | 1 |
| Hemoglobin-BELOW-BELOW | 7 | 6 | 2 | 6 | 3 | 6 | 5 | 3 | 8 | 3 |
| Hemoglobin-BELOW-WITHIN | 1 | 2 | 1 | 1 | 2 | 3 | 1 | 0 | 1 | 1 |
| Hemoglobin-WITHIN-UNKNOWN | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Hemoglobin-WITHIN-BELOW | 5 | 2 | 0 | 0 | 3 | 1 | 1 | 1 | 3 | 2 |
| Hemoglobin-WITHIN-WITHIN | 81 | 83 | 89 | 86 | 86 | 82 | 89 | 90 | 82 | 91 |
| Hemoglobin-WITHIN-ABOVE | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin-ABOVE-WITHIN | 0 | 1 | 1 | 2 | 0 | 2 | 0 | 1 | 0 | 0 |
| Hemoglobin-ABOVE-ABOVE | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 |
| Lymphocytes-UNKNOWN-WITHIN | 1 | 0 | 1 | 0 | 2 | 2 | 2 | 1 | 2 | 1 |
| Lymphocytes-BELOW-BELOW | 0 | 0 | 0 | 2 | 1 | 1 | 2 | 0 | 0 | 4 |
| Lymphocytes-BELOW-WITHIN | 2 | 1 | 4 | 2 | 3 | 1 | 1 | 1 | 1 | 1 |
| Lymphocytes-WITHIN-UNKNOWN | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Lymphocytes-WITHIN-BELOW | 2 | 0 | 0 | 1 | 1 | 0 | 2 | 1 | 0 | 1 |
| Lymphocytes-WITHIN-WITHIN | 90 | 91 | 89 | 90 | 88 | 92 | 91 | 94 | 94 | 91 |
| Lymphocytes-WITHIN-ABOVE | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes-ABOVE-WITHIN | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes-ABOVE-ABOVE | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Monocytes-UNKNOWN-BELOW | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Monocytes-UNKNOWN-WITHIN | 1 | 0 | 1 | 0 | 2 | 2 | 2 | 1 | 1 | 1 |
| Monocytes-BELOW-BELOW | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 3 |
| Monocytes-BELOW-WITHIN | 3 | 0 | 4 | 3 | 3 | 5 | 4 | 3 | 4 | 3 |
| Monocytes-WITHIN-UNKNOWN | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Monocytes-WITHIN-BELOW | 1 | 2 | 3 | 2 | 1 | 6 | 1 | 3 | 1 | 3 |
| Monocytes-WITHIN-WITHIN | 87 | 92 | 87 | 91 | 90 | 82 | 91 | 88 | 89 | 88 |
| Monocytes-ABOVE-WITHIN | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Monocytes-ABOVE-ABOVE | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Neutrophils-UNKNOWN-WITHIN | 1 | 0 | 1 | 0 | 2 | 2 | 2 | 1 | 2 | 1 |
| Neutrophils-BELOW-BELOW | 1 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 2 |
| Neutrophils-BELOW-WITHIN | 1 | 0 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 0 |
| Neutrophils-WITHIN-UNKNOWN | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Neutrophils-WITHIN-BELOW | 0 | 1 | 3 | 1 | 1 | 1 | 2 | 0 | 4 | 2 |
| Neutrophils-WITHIN-WITHIN | 92 | 90 | 90 | 90 | 91 | 90 | 92 | 95 | 89 | 92 |
| Neutrophils-WITHIN-ABOVE | 1 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 |
| Neutrophils-ABOVE-WITHIN | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Neutrophils-ABOVE-ABOVE | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets-UNKNOWN-UNKNOWN | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Platelets-UNKNOWN-WITHIN | 2 | 2 | 2 | 0 | 2 | 2 | 5 | 2 | 2 | 1 |
| Platelets-BELOW-UNKNOWN | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets-BELOW-BELOW | 3 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 2 |
| Platelets-BELOW-WITHIN | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| Platelets-WITHIN-UNKNOWN | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
| Platelets-WITHIN-BELOW | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Platelets-WITHIN-WITHIN | 88 | 89 | 88 | 91 | 92 | 88 | 87 | 90 | 89 | 91 |
| Platelets-WITHIN-ABOVE | 0 | 1 | 1 | 2 | 2 | 0 | 2 | 1 | 3 | 1 |
| Platelets-ABOVE-WITHIN | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| Platelets-ABOVE-ABOVE | 1 | 0 | 1 | 2 | 0 | 1 | 0 | 2 | 1 | 3 |
| Urea Nitrogen-UNKNOWN-WITHIN | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 0 |
| Urea Nitrogen-UNKNOWN-ABOVE | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Urea Nitrogen-BELOW-BELOW | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Urea Nitrogen-BELOW-WITHIN | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Urea Nitrogen-WITHIN-UNKNOWN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Urea Nitrogen-WITHIN-WITHIN | 91 | 94 | 93 | 91 | 95 | 94 | 91 | 91 | 91 | 97 |
| Urea Nitrogen-WITHIN-ABOVE | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Urea Nitrogen-ABOVE-WITHIN | 1 | 0 | 2 | 1 | 3 | 1 | 2 | 2 | 2 | 0 |
| Urea Nitrogen-ABOVE-ABOVE | 3 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 |
| Uric Acid-UNKNOWN-BELOW | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Uric Acid-UNKNOWN-WITHIN | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 |
| Uric Acid-UNKNOWN-ABOVE | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Uric Acid-BELOW-BELOW | 1 | 2 | 0 | 3 | 0 | 1 | 4 | 2 | 2 | 2 |
| Uric Acid-BELOW-WITHIN | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Uric Acid-WITHIN-UNKNOWN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Uric Acid-WITHIN-BELOW | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 3 |
| Uric Acid-WITHIN-WITHIN | 91 | 86 | 87 | 89 | 98 | 91 | 92 | 87 | 91 | 83 |
| Uric Acid-WITHIN-ABOVE | 0 | 0 | 4 | 1 | 0 | 0 | 0 | 3 | 1 | 4 |
| Uric Acid-ABOVE-WITHIN | 1 | 2 | 1 | 2 | 0 | 2 | 0 | 2 | 1 | 4 |
| Uric Acid-ABOVE-ABOVE | 2 | 3 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
| White Blood Cells-UNKNOWN-WITHIN | 1 | 0 | 1 | 0 | 2 | 2 | 2 | 1 | 2 | 1 |
| White Blood Cells-BELOW-BELOW | 2 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 4 |
| White Blood Cells-BELOW-WITHIN | 2 | 0 | 2 | 3 | 4 | 4 | 6 | 2 | 2 | 1 |
| White Blood Cells-WITHIN-UNKNOWN | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| White Blood Cells-WITHIN-BELOW | 3 | 0 | 2 | 3 | 3 | 2 | 1 | 0 | 3 | 1 |
| White Blood Cells-WITHIN-WITHIN | 86 | 92 | 89 | 86 | 83 | 88 | 88 | 91 | 88 | 90 |
| White Blood Cells-WITHIN-ABOVE | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 1 |
| White Blood Cells-ABOVE-WITHIN | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 |
| White Blood Cells-ABOVE-ABOVE | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.
| Participants | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | 1 | 0 | 0 | 0 | 1 | 1 | 4 | 3 | 7 | 1 | 7 | 6 | 8 | 4 |
| General adverse event | 1 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 5 | 0 | 2 | 3 | 4 | 4 |
| Local adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 6 | 3 | 4 | 0 |
A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.
| Participants | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 5 | 3 | 5 | 8 | 7 | 3 | 0 |
| General adverse event | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 4 | 2 | 2 | 5 | 5 | 1 | 0 |
| Local adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 4 | 2 | 2 | 0 |
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.
| Participants | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination | 0 | 0 | 0 | 0 | 6 | 0 | 1 | 4 | 2 | 1 | 1 | 3 | 5 | 1 |
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
| Participants | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.
| Participants | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups | 13 | 3 | 5 | 8 | 6 | 11 | 9 | 5 | 9 | 9 |
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
| Participants | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
The number of subjects with at least one RTI case was provided by group. Reported categories are RSV+ (= RTI episode tested as RSV positive by quantitative reverse transcription polymerase chain reaction (qRT-PCR) on nasal/throat swab) and RSV- (= RTI episode tested as RSV negative by qRT-PCR on nasal/throat swab).
| Participants | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|
| RSV+ | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 |
| RSV- | 19 | 12 | 20 | 14 | 17 | 22 | 20 | 16 | 13 | 11 |
Serological assays for the determination of functional antibodies against RSV-A were performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as geometric mean titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60).
| Titers | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 1019 (634.6 to 1636.1) | 846.2 (481.7 to 1486.4) | 673.6 (325.3 to 1394.7) | 620.7 (365.1 to 1055.1) | 1015.5 (865 to 1192.2) | 1146.5 (931.6 to 1411) | 976.7 (837.7 to 1138.8) | 960.9 (801 to 1152.7) | 966.4 (822.9 to 1134.8) | 961.9 (809.5 to 1143) | 981.6 (832.7 to 1157.2) | 1023 (879.2 to 1190.2) | 1035.7 (864.5 to 1240.7) | 837.4 (701.3 to 999.9) |
| Day 31 | 7658.4 (4329.7 to 13546.2) | 11741.8 (4883.6 to 28231.5) | 8136.9 (5066.1 to 13069.1) | 789.1 (518.6 to 1200.9) | 5422.6 (4395 to 6690.5) | 7371 (5922.5 to 9173.8) | 9403.1 (7471.2 to 11834.4) | 5258.5 (4351.8 to 6354.1) | 6509.4 (5306.8 to 7984.4) | 9350.9 (7606 to 11496.1) | 6026.1 (4960.9 to 7320.1) | 6899.5 (5767.8 to 8253.2) | 8527.7 (7107.9 to 10231) | 751.7 (625.2 to 903.9) |
| Day 61 | 4659.8 (2090 to 10389.1) | 5895.8 (2791.9 to 12450.5) | 4761.5 (2687.7 to 8435.5) | 586.5 (333.1 to 1032.7) | 5657.9 (4736 to 6759.1) | 6490.8 (5190.3 to 8117.1) | 7907.4 (6253.9 to 9998.2) | 5019.4 (4281.5 to 5884.5) | 6201.9 (5106.3 to 7532.6) | 6681.7 (5498.4 to 8119.8) | 5048.9 (4184.4 to 6092) | 5902.1 (5023.4 to 6934.4) | 7201.4 (6000.4 to 8642.8) | 903.4 (750.8 to 1087.1) |
| Day 91 | 6237.8 (3648.1 to 10665.9) | 5457.5 (2532.9 to 11758.7) | 3651 (1949.6 to 6837.2) | 787.9 (495.5 to 1252.6) | 3936.2 (3281.9 to 4720.9) | 5632.1 (4559.2 to 6957.5) | 5956.1 (4881.4 to 7267.4) | 3924.7 (3266 to 4716.2) | 4770 (3904.6 to 5827.4) | 5175.5 (4273.1 to 6268.5) | 4435.9 (3654.7 to 5384.1) | 4850.5 (4096.8 to 5742.8) | 5980.6 (4988 to 7170.7) | 772.4 (646.2 to 923.3) |
The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples were based on an indirect enzyme-linked immunosorbent assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL).
| ELU/mL | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 8330.7 (5561.5 to 12478.9) | 7699.5 (5326 to 11130.8) | 7439.1 (5808.6 to 9527.2) | 6524.8 (4828.2 to 8817.6) | 7500.2 (6582.4 to 8545.9) | 7209.7 (6150.9 to 8450.7) | 7134.9 (6377.7 to 7982) | 6760.5 (5913.7 to 7728.5) | 7438 (6544.6 to 8453.4) | 6685.4 (5827 to 7670.4) | 7468.5 (6544 to 8523.5) | 7245.5 (6265.8 to 8378.3) | 6655.4 (5862.2 to 7555.9) | 6543.8 (5663 to 7561.6) |
| Day 31 | 69843.3 (38345.8 to 127212.8) | 97848.5 (65057.1 to 147168) | 96645.4 (62880.7 to 148540.5) | 6601 (4888.4 to 8913.6) | 53994 (46566.7 to 62605.8) | 71618.4 (60729.6 to 84459.5) | 90933.2 (79096.2 to 104541.6) | 53598.9 (47062.7 to 61043) | 63823.4 (55601.6 to 73261) | 83462.5 (70906.1 to 98242.3) | 59026.1 (51236.4 to 68000) | 70524 (60825.4 to 81769.1) | 78831.2 (68382.5 to 90876.4) | 6593.4 (5672 to 7664.4) |
| Day 61 | 50590.1 (27310.9 to 93711.7) | 58980.8 (38982.8 to 89237.7) | 56380.6 (38602.6 to 82346.1) | 6242.4 (4473 to 8711.7) | 47594.2 (41241.9 to 54924.8) | 56855.4 (47655.2 to 67831.7) | 70294.1 (61103.1 to 80867.5) | 41543.8 (36864.7 to 46816.8) | 51209.9 (44850.5 to 58470.9) | 62543.2 (52975.1 to 73839.3) | 45679.1 (39722.6 to 52528.7) | 54342.7 (47099 to 62700.5) | 61577.7 (53431.3 to 70966.1) | 6307.9 (5453.8 to 7295.9) |
| Day 91 | 54900 (33635.4 to 89608.2) | 54884.7 (37768.6 to 79757.3) | 55444.4 (38128.6 to 80624) | 6246 (4375.8 to 8915.7) | 42523.7 (36905 to 48997.8) | 54711.2 (47013.5 to 63669.2) | 60955.2 (53029.7 to 70065.1) | 42504.6 (38044.3 to 47487.9) | 52846.4 (47105.8 to 59286.7) | 59624.5 (51680 to 68790.2) | 53779.9 (47588.5 to 60776.8) | 57314.9 (51038.1 to 64363.6) | 61433.7 (54066.2 to 69805) | 6748.7 (5804.1 to 7847.1) |
Among markers expressed were interleukin-2 (IL2), cluster of 40 ligand (CD40L), tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations. Reported statistics at each time point during which blood sample were collected for cell-mediated immunity, are geometric mean and inter-quartile range.
| Cells per million CD4+ T Cells | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 400.0 (348 to 791) | 272.0 (163 to 570) | 317.5 (184 to 628) | 393.0 (333 to 680) | 208.5 (84 to 351) | 166.0 (75 to 291) | 225.5 (109 to 327) | 209.5 (127 to 338) | 188.0 (103 to 326) | 192.0 (67 to 381) | 187.5 (91 to 325.5) | 185.0 (82 to 294) | 206.0 (98 to 351) | 178.0 (100.5 to 293.5) |
| Day 31 | 1649.0 (864 to 2604) | 2302.5 (1545 to 2725) | 1773.5 (1318 to 2124) | 303.0 (90 to 416) | 979.5 (639.5 to 1422.5) | 1089.5 (786 to 1812.5) | 1052.0 (674.5 to 1798) | 1594.0 (916 to 2360) | 1297.0 (881 to 2321) | 1466.0 (787 to 2116) | 1952.0 (1353 to 2953) | 1690.5 (1162.5 to 2691.5) | 1742.5 (1088 to 2360.5) | 176.0 (85 to 297) |
| Day 61 | 1271.0 (519 to 1679) | 1515.0 (1129 to 2159) | 1066.0 (764 to 1502) | 263.0 (184 to 459) | 688.0 (430 to 1076) | 737.0 (437 to 1309) | 770.0 (479 to 1235) | 1086.0 (663 to 1621) | 1020.0 (603 to 1405) | 934.0 (598 to 1517) | 1228.5 (777.5 to 1832.5) | 1315.0 (887 to 1728) | 1078.0 (781 to 1631) | 183.0 (61 to 311) |
| Day 91 | 1006.5 (872 to 1779) | 1221.0 (924 to 1518) | 1487.0 (1005 to 1664) | 374.5 (295 to 588) | 888.0 (650 to 1318) | 1034.0 (670 to 1598) | 1081.5 (769 to 1569) | 1732.0 (1163 to 2149) | 1603.5 (1087 to 2284) | 1496.0 (1179 to 2072) | 1966.0 (1339 to 2700) | 1558.0 (1263 to 2353) | 2096.5 (1441.5 to 2760.5) | 190.5 (100.5 to 308) |
Collected over Solicited AEs were collected during the 7-day follow-up period after each vaccination. Unsolicited AEs were collected during the 30-day follow-up period after any vaccination. SAEs were collected during the whole study period, from Day 1 till Day 91 for Part A groups and till Month 14 for Part B groups.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dose_PLAIN_A Group | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| Medium Dose_PLAIN_A Group | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| High Dose_PLAIN_A Group | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| Placebo_A Group | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Low Dose_PLAIN_B Group | 0/101 (0%) | 13/101 (12.9%) | 62/101 (61.4%) |
| Medium Dose_PLAIN_B Group | 1/97 (1%) | 3/97 (3.1%) | 54/97 (55.7%) |
| High Dose_PLAIN_B Group | 1/100 (1%) | 5/100 (5%) | 61/100 (61%) |
| Low Dose_AS01E_B Group | 0/101 (0%) | 8/101 (7.9%) | 77/101 (76.2%) |
| Medium Dose_AS01E_B Group | 0/101 (0%) | 6/101 (5.9%) | 80/101 (79.2%) |
| High Dose_AS01E_B Group | 0/100 (0%) | 11/100 (11%) | 83/100 (83%) |
| Low Dose_AS01B_B Group | 1/103 (1%) | 9/103 (8.7%) | 91/103 (88.3%) |
| Medium Dose_AS01B_B Group | 0/100 (0%) | 5/100 (5%) | 88/100 (88%) |
| High Dose_AS01B_B Group | 1/101 (1%) | 9/101 (8.9%) | 93/101 (92.1%) |
| Placebo_B Group | 0/101 (0%) | 9/101 (8.9%) | 54/101 (53.5%) |
| Event | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/12 | 0/12 | 0/12 | 0/12 | 1/101 | 0/97 | 0/100 | 0/101 | 0/101 | 1/100 | 0/103 | 2/100 | 0/101 | 0/101 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/12 | 0/12 | 0/12 | 0/12 | 1/101 | 0/97 | 0/100 | 1/101 | 2/101 | 0/100 | 0/103 | 0/100 | 0/101 | 1/101 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/12 | 0/12 | 0/12 | 0/12 | 1/101 | 0/97 | 0/100 | 2/101 | 0/101 | 0/100 | 1/103 | 0/100 | 1/101 | 0/101 |
| Back painMusculoskeletal and connective tissue disorders | 0/12 | 0/12 | 0/12 | 0/12 | 1/101 | 0/97 | 1/100 | 0/101 | 0/101 | 0/100 | 2/103 | 0/100 | 0/101 | 0/101 |
| Cardio-respiratory arrestCardiac disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/101 | 1/97 | 0/100 | 0/101 | 0/101 | 0/100 | 0/103 | 0/100 | 0/101 | 0/101 |
| DeathGeneral disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/101 | 1/97 | 1/100 | 0/101 | 0/101 | 0/100 | 1/103 | 0/100 | 1/101 | 0/101 |
| Patella fractureInjury, poisoning and procedural complications | 0/12 | 0/12 | 0/12 | 0/12 | 0/101 | 1/97 | 0/100 | 0/101 | 0/101 | 0/100 | 0/103 | 0/100 | 0/101 | 0/101 |
| Ischaemic strokeNervous system disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/101 | 1/97 | 0/100 | 0/101 | 0/101 | 0/100 | 0/103 | 0/100 | 0/101 | 0/101 |
| Aortic aneurysm ruptureVascular disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/101 | 1/97 | 0/100 | 0/101 | 0/101 | 0/100 | 0/103 | 0/100 | 0/101 | 0/101 |
| Shock haemorrhagicVascular disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/101 | 1/97 | 0/100 | 0/101 | 0/101 | 0/100 | 0/103 | 0/100 | 0/101 | 0/101 |
| Event | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 6/12 | 9/12 | 8/12 | 1/12 | 23/101 | 19/97 | 31/100 | 60/101 | 63/101 | 65/100 | 81/103 | 78/100 | 82/101 | 8/101 |
| FatigueGeneral disorders | 5/12 | 5/12 | 4/12 | 7/12 | 29/101 | 20/97 | 29/100 | 41/101 | 39/101 | 36/100 | 45/103 | 47/100 | 53/101 | 24/101 |
| HeadacheNervous system disorders | 3/12 | 5/12 | 5/12 | 5/12 | 16/101 | 14/97 | 17/100 | 28/101 | 25/101 | 24/100 | 45/103 | 38/100 | 38/101 | 13/101 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/12 | 1/12 | 1/12 | 0/12 | 5/101 | 6/97 | 5/100 | 14/101 | 12/101 | 15/100 | 28/103 | 22/100 | 32/101 | 9/101 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/12 | 0/12 | 0/12 | 0/12 | 9/101 | 8/97 | 4/100 | 14/101 | 19/101 | 18/100 | 28/103 | 19/100 | 24/101 | 11/101 |
| Gastrointestinal disorderGastrointestinal disorders | 2/12 | 2/12 | 2/12 | 3/12 | 11/101 | 9/97 | 14/100 | 13/101 | 11/101 | 15/100 | 18/103 | 12/100 | 19/101 | 13/101 |
| Upper respiratory tract infectionInfections and infestations | 0/12 | 1/12 | 1/12 | 3/12 | 3/101 | 3/97 | 4/100 | 3/101 | 4/101 | 3/100 | 4/103 | 2/100 | 6/101 | 2/101 |
| ErythemaSkin and subcutaneous tissue disorders | 0/12 | 1/12 | 0/12 | 0/12 | 1/101 | 1/97 | 4/100 | 7/101 | 9/101 | 14/100 | 24/103 | 20/100 | 24/101 | 1/101 |
| ChillsGeneral disorders | 0/12 | 2/12 | 0/12 | 1/12 | 2/101 | 1/97 | 2/100 | 11/101 | 7/101 | 6/100 | 21/103 | 19/100 | 19/101 | 3/101 |
| Injection site swellingGeneral disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/101 | 1/97 | 4/100 | 8/101 | 9/101 | 11/100 | 17/103 | 9/100 | 14/101 | 0/101 |
| Age, Continuous(Years) | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 31.2 ± 7.0 | 26.5 ± 4.0 | 29.9 ± 6.1 | 31.6 ± 5.6 | 67.3 ± 5.6 | 67.8 ± 5.6 | 67.9 ± 4.9 | 67.8 ± 5.1 | 67.1 ± 5.6 | 67.6 ± 5.2 | 67.6 ± 4.9 | 67.5 ± 4.9 | 67.5 ± 4.9 | 68.1 ± 5.7 | 65.9 ± 9.5 |
| Sex: Female, Male(Participants) | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 8 | 7 | 7 | 9 | 58 | 54 | 57 | 58 | 57 | 57 | 59 | 58 | 57 | 58 | 604 |
| Male | 4 | 5 | 5 | 3 | 43 | 43 | 43 | 43 | 44 | 43 | 44 | 42 | 44 | 43 | 449 |
| Race/Ethnicity, Customized(Participants) | Low Dose_PLAIN_A Group | Medium Dose_PLAIN_A Group | High Dose_PLAIN_A Group | Placebo_A Group | Low Dose_PLAIN_B Group | Medium Dose_PLAIN_B Group | High Dose_PLAIN_B Group | Low Dose_AS01E_B Group | Medium Dose_AS01E_B Group | High Dose_AS01E_B Group | Low Dose_AS01B_B Group | Medium Dose_AS01B_B Group | High Dose_AS01B_B Group | Placebo_B Group | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMERICAN INDIAN OR ALASKA NATIVE | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| ASIAN | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| BLACK OR AFRICAN AMERICAN | 2 | 1 | 2 | 1 | 5 | 7 | 4 | 12 | 7 | 5 | 11 | 7 | 7 | 4 | 75 |
| OTHER | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 5 |
| WHITE | 10 | 10 | 10 | 11 | 95 | 90 | 93 | 88 | 94 | 93 | 92 | 93 | 92 | 97 | 968 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jan 2019 to primary completion in Dec 2019, 10 months.
Results were first posted in Mar 2022, 2 years 3 months after primary completion. A results delay was requested in Dec 2020.
Of 16 phase 1/2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Syncytial Virus Infections →